Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611001003965
Ethics application status
Approved
Date submitted
19/09/2011
Date registered
20/09/2011
Date last updated
20/09/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
The average level of blood thinning, resulting from an individual weight determined dose of Clexane, when given to women after caesarian section to prevent blood clots.
Query!
Scientific title
The effect of a weight-based enoxaparin thromboprophylaxis on antiXa levels in women post caesarian section.
Query!
Secondary ID [1]
263032
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1124-5054
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
thromboprophylaxis for caesarian section
270758
0
Query!
Condition category
Condition code
Blood
270938
270938
0
0
Query!
Clotting disorders
Query!
Reproductive Health and Childbirth
270939
270939
0
0
Query!
Childbirth and postnatal care
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Enoxaparin dose is based upon patient weight at time of confinement booking (usually 6 - 12 weeks gestation)
Dosage schedule is:
Less than 40 kg 20 IU subcutaneous daily
> 40 to 90kg 40 IU subcutaneous daily
> 90 to 130 kg 60 IU subcutaneous daily
> 130 to 170 kg 80 IU subcutaneous daily
> 170 kg 0.5 IU/kg subcutaneous twice daily
Administered day 1,2 and 3 post partum
Query!
Intervention code [1]
269373
0
Treatment: Drugs
Query!
Intervention code [2]
269424
0
Prevention
Query!
Comparator / control treatment
NIL
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
279607
0
plasma AntiXa levels
Query!
Assessment method [1]
279607
0
Query!
Timepoint [1]
279607
0
baseline, 4 hours post first & third doses
Query!
Secondary outcome [1]
294028
0
Nil
Query!
Assessment method [1]
294028
0
Query!
Timepoint [1]
294028
0
Nil
Query!
Eligibility
Key inclusion criteria
post caesarian section.
patient classified as high or intermediate risk of VTE based upon BCOG guidelines 2009
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
refusal to enter trial
no booking maternal weight obtainable
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
convenience sampling to fill weight based strata
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
N/A
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Pharmacokinetics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
19/09/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
269832
0
Hospital
Query!
Name [1]
269832
0
Mercy Hospital For Women
Query!
Address [1]
269832
0
163 Studley Road
Heidelberg Victoria 3084
Query!
Country [1]
269832
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Mercy Hospital For Women
Query!
Address
163 Studley Road
Heidelberg Victoria 3084
Query!
Country
Australia
Query!
Secondary sponsor category [1]
268864
0
None
Query!
Name [1]
268864
0
Query!
Address [1]
268864
0
Query!
Country [1]
268864
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
271855
0
Query!
Ethics committee address [1]
271855
0
Query!
Ethics committee country [1]
271855
0
Query!
Date submitted for ethics approval [1]
271855
0
Query!
Approval date [1]
271855
0
Query!
Ethics approval number [1]
271855
0
R11/35
Query!
Summary
Brief summary
Following major surgery patients are at increased risk of developing blood clots in the veins of the lower limb and in some patients these may dislodge, travel to the lung as pulmonary emboli, resulting in breathing difficulties and rarely death. The situation is no different after caesarian section, where patients are at increased risk of blood clots, however the risk is not the same for all but influenced by factors such as previous history of blood clots, the need for emergency surgery, age and body weight.
After your surgery we can minimize the risk of blood clots by mobilizing you as soon as possible, using below knee compression stockings, which prevent pooling of blood in calf veins and in certain patients by once daily injections under the skin of a blood thinning low molecular weight heparin drug (LMWH) called enoxaparin. For many years the dose of enoxaparin has been fixed and not adjusted for body weight, however there is evidence from studies in overweight non-pregnant patients that as body weight increases an increase in dose is required to maintain prevention. Pregnancy also alters the way these enoxaparin is handled by the body resulting in an increase in the dose required (at the end of pregnancy and immediately after delivery) to provide the same action as in the non-pregnant patient.
Recently, the Royal College of Obstetrician and Gynaecologists (RCOG) in the United Kingdom have updated their guidelines for prevention of thrombosis after caesarian section and recommend that patients classified as intermediate risk or greater should be given LMWH with the dose determined by their actual body weight at 8 -16 weeks of gestation (usually referred to as the booking weight).
We believe that you fall into the intermediate (or high) risk category and therefore would benefit from having LMWH preventative treatment. The dose given to you will be that recommended by the RCOG guideline and will be calculated based on your body weight at the time of registering for care at the Mercy Hospital for Women. For patients of less than 90 kg you will receive what for many years has been the standard dose of enoxaparin. For patients above 90 kg you will receive a dose greater than this fixed dose, which we believe is safe and is likely to result in better prevention of clots compared to the usual dose.
We are asking that you consent to having three samples of blood (10 mls each) taken and analyzed for LMWH blood thinning activity (antiXa levels). The first and second samples will be taken immediately prior to & then four hours after your first preventative injection some 4-12 hours after completion of your caesarian section. A third sample will be taken four hours after your third or fourth dose given on the day prior to your discharge from hospital. An additional small plastic cannula will be inserted into a arm vein at the time of your caesarian section and the first blood sample taken at that time. A second sample, hopefully via the cannula, will be taken 3 – 5 hours after the injection of Enoxaparin some 4-12 hours after your caesarian delivery. The third sample will require a separate blood test to be taken.
The study does not change the obstetric or anaesthetic management of your delivery. Breast feeding is considered safe whilst on enoxaparin.
All blood thinners lead to a slightly increased risk of wound and uterine bleeding. We don't believe that the risk of bleeding is increased over that seen in non pregnant patients given enoxaparin to prevent blood clots following surgery.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33148
0
Query!
Address
33148
0
Query!
Country
33148
0
Query!
Phone
33148
0
Query!
Fax
33148
0
Query!
Email
33148
0
Query!
Contact person for public queries
Name
16395
0
Clin Assoc Prof Scott Simmons
Query!
Address
16395
0
Mercy Hospital for Women
163 Studley Road
Heidelberg Victoria 3084
Query!
Country
16395
0
Australia
Query!
Phone
16395
0
61 0384584113
Query!
Fax
16395
0
Query!
Email
16395
0
[email protected]
Query!
Contact person for scientific queries
Name
7323
0
Clin Assoc Prof Scott Simmons
Query!
Address
7323
0
Department of Anaesthesia
Mercy Hospital for Women
163 Studley Road
Heidelberg Victoria 3084
Query!
Country
7323
0
Australia
Query!
Phone
7323
0
61 03 84584113
Query!
Fax
7323
0
Query!
Email
7323
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF